Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
153 hedge funds and large institutions have $1.4B invested in Acorda Therapeutics in 2013 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 68 increasing their positions, 45 reducing their positions, and 16 closing their positions.
51% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 45
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
25% more call options, than puts
Call options by funds: $4.22M | Put options by funds: $3.36M
6% more capital invested
Capital invested by funds: $1.32B → $1.4B (+$80.1M)
3% more funds holding
Funds holding: 148 → 153 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$17.9M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$11.6M |
| 3 |
Goldman Sachs
New York
|
+$9.3M |
| 4 |
ClearBridge Investments
New York
|
+$7.92M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$6.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$14.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.8M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$10.9M |
| 4 |
SCM
Sigma Capital Management
Stamford,
Connecticut
|
-$6.22M |
| 5 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
-$6.16M |
ACOR Hedge Fund Activity: Q3 2013 in Review
153 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q3 2013, worth a combined $1.4B — up 6.1% from $1.32B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ACOR positions and 16 closed out — a net gain of 6 holders — while 68 added to existing stakes and 45 trimmed.
The largest buyer was Thrivent Financial for Lutherans, adding an estimated $17.9M. The largest seller was Artal Group, cutting an estimated $14.5M.
- 153 institutional investors held Acorda Therapeutics (ACOR) as of Q3 2013, up from 148 in Q2 2013.
- Funds reported $1.4B of Acorda Therapeutics stock for Q3 2013, up 6.1% quarter-over-quarter.
- 22 funds opened new Acorda Therapeutics positions in Q3 2013 and 16 closed out, a net change of +6 holders.
- The largest Acorda Therapeutics buyer in Q3 2013 was Thrivent Financial for Lutherans, an estimated $17.9M added.
- The largest Acorda Therapeutics seller in Q3 2013 was Artal Group, an estimated $14.5M sold.
Based on aggregated 13F filings for Q3 2013.